Celgene ( CELG +0.8% ) gets an Orphan designation for sotatercept in beta-thalassemia intermedia and major. ( FDA ) 1 comment!
out with a $46 target (from $27). Wei likes the Celgene ( CELG ) deal and says it "validates demcizumab and [the] cancer stem ..... relieves OMED of any near-term financing risk." For more on the CELG deal, see here Post your comment!
By SA Editor Miriam Metzinger : Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Tuesday December 3. Bullish Calls: Xilinx ( XLNX ): "The one I'm buying is Xilinx." Lumber Liquidators ( LL ): "This is a high growth stock that might catch a bid. Let's not sell it ...
By Brian L. Wilson : After some new and aggressive developments, we are once again taking a look at Sorrento Therapeutics (NASDAQ: SRNE ) . We believe that the acquisition of Concortis Biosystems , and the technology that the company possessed, adds significant potential to the company when ...
Celgene Corporation ( CELG ) Company Conference Presentation December 2, 2013 9:00 am ET Executives Jacqualyn Fouse – Executive Vice President, Chief Financial
By Peter Geschek : Celgene's ( CELG ) drug Pomalyst has been approved later and is selling better than Amgen's ( AMGN ) Kyprolis. Pomalyst, approved this past
Piper starts Celgene ( CELG ) at Neutral. Repros Therapeutics ( RPRX ) initiated at Overweight at Piper. Price target is $26. Piper starts Gilead ( GILD
By SA Editor Miriam Metzinger : Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Friday November 22. 11 Things To Watch In The Week Ahead: Workday ( WDAY ), Palo Alto Networks ( PANW ), Hewlett-Packard ( HPQ ), Tivo ( TIVO ), Tiffany ( TIF ), Cracker Barrel ( CBRL ),
By Abba's Aces : The last time I wrote about Amgen ( AMGN ) I bought a small batch in it stating that was a good value at the time. Since the last article it actually shot up 7% excluding the dividend (it is up 7.41% including the dividend) versus the 8.46% gain the S&P500 ( SPY ) posted. Amgen is
By Bio Vantage : Back in March 2013, Johnson and Johnson ( JNJ ) was trading around $81. At the time, we wrote a report on Johnson and Johnson based on its 2012 financial data. Our DCF model suggested that JNJ's intrinsic equity value was around $86-$92, assuming an earnings growth rate of 4.5%-5%